about
New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic eventsEducating orally anticoagulated patients in drug safety: a cluster-randomized study in general practiceNovel oral anticoagulants in non-valvular atrial fibrillation.Edoxaban: Review of pharmacology and key phase I to III clinical trials.Potential use of NOACs in developing countries: pros and cons.Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.
P2860
Q28080616-0079854D-10EC-44A9-B087-43D4912D4F96Q34295187-CF205C0E-104C-41C7-86E9-3436D6E79D8FQ34666804-567A3E1B-3541-471C-8A6C-4BCD88C029E3Q38194364-46A45243-5365-4AAC-B242-6CBB6E3B1EF6Q38210994-44D0D973-E319-43A0-B7DA-2B63DB242CF1Q38221812-DB6C5F70-44D1-462A-BD40-F383BAFFC6D3Q38386998-D25DF8C8-A5EF-4CC4-BEEB-E963AF1C4C97
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Novel oral anticoagulants in cardiovascular disease.
@en
type
label
Novel oral anticoagulants in cardiovascular disease.
@en
prefLabel
Novel oral anticoagulants in cardiovascular disease.
@en
P2860
P356
P1476
Novel oral anticoagulants in cardiovascular disease.
@en
P2093
Pilar Gallego
Vanessa Roldán
P2860
P356
10.1177/1074248413501392
P577
2013-09-13T00:00:00Z